Because most people have cabozantinib, lenvatinib or sorafenib, these are the treatment options modelled in the template. Selpercatinib and the comparators are oral treatments. The company has a ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

Your plan's summary annual report offers a concise look at its finances Greg Daugherty has worked 25+ years as an editor and writer for major publications and websites. He is also the author of ...